Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Leukemia, Myeloid, Acute 3Ovarian Neoplasms 2Myelodysplastic Syndromes 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Paraganglioma 1Myeloproliferative Disorders 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Imatinib Mesylate 27regorafenib 8nilotinib 6Sunitinib 6pazopanib 3Temozolomide 3Paclitaxel 3Nivolumab 3Ipilimumab 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3trametinib 2spartalizumab 2ripretinib 2ponatinib 2envafolimab 2Specimen Handling 2Sorafenib 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Laparoscopy 2Dasatinib 2Carboplatin 2CTLA-4 Antigen 25-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 2vatalanib 1temsirolimus 1rubitecan 1romidepsin 1perifosine 1pemigatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastrointestinal Stromal Tumors × guadecitabine × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡